Table 1 Distribution of patients on the basis of clinicopathological features and time delay
Variable | N | ≤60 days | N | 60–120 days | N | >120 days | p value |
|---|---|---|---|---|---|---|---|
N. group | 53 | 298 | 264 | ||||
Age | |||||||
≤50 | 53 | 31 (58.49) | 298 | 85 (28.52) | 264 | 56 (21.21) | <0.0001 |
>50 | 53 | 22 (41.51) | 298 | 213 (71.48) | 264 | 208 (78.79) | |
Grading | |||||||
G1 | 32 | 9 (28.13) | 228 | 63 (27.63) | 219 | 71 (32.42) | 0.741 |
G2 | 32 | 20 (62.50) | 228 | 132 (57.89) | 219 | 118 (53.88) | |
G3 | 32 | 3 (9.38) | 228 | 33 (14.47) | 219 | 30 (13.70) | |
Hystologic type | |||||||
Ductal infiltrating | 52 | 39 (75.00) | 297 | 225 (75.76) | 264 | 176 (66.67) | 0.2576 |
Lobular infiltrating | 52 | 5 (9.62) | 297 | 16 (5.39) | 264 | 21 (7.95) | |
Ductal in situ | 52 | 4 (7.69) | 297 | 32 (10.77) | 264 | 35 (13.26) | |
Other | 52 | 4 (7.69) | 297 | 24 (8.08) | 264 | 32 (12.12) | |
Margins | |||||||
Negative | 53 | 52 (98.11) | 298 | 292 (97.99) | 264 | 251 (95.08) | 0.0716 |
Close | 53 | 0 (0.00) | 298 | 3 (1.01) | 264 | 1 (0.38) | |
Positive | 53 | 1 (1.89) | 298 | 3 (1.01) | 264 | 12 (4.55) | |
Hormone therapy | |||||||
No | 34 | 3 (8.82) | 258 | 14 (5.43) | 239 | 21 (8.79) | 0.323 |
Yes | 34 | 31 (91.18) | 258 | 244 (94.57) | 239 | 218 (91.21) | |
Estrogen receptor status | |||||||
Negative | 35 | 2 (5.71) | 267 | 14 (5.24) | 248 | 17 (6.85) | 0.7418 |
Positive | 35 | 33 (94.29) | 267 | 253 (94.76) | 248 | 231 (93.15) | |
Site | |||||||
Right breast | 53 | 24 (45.28) | 291 | 140 (48.11) | 257 | 139 (54.09) | 0.2778 |
Left breast | 53 | 29 (54.72) | 291 | 151 (51.89) | 257 | 118 (45.91) | |
T stage | |||||||
DCIS | 53 | 5 (9.43) | 298 | 44 (14.77) | 264 | 52 (19.70) | 0.2187 |
T1 | 53 | 38 (71.70) | 298 | 216 (72.48) | 264 | 180 (68.18) | |
T2 | 53 | 10 (18.87) | 298 | 38 (12.75) | 264 | 32 (12.12) | |
Hormone therapy type | |||||||
None | 33 | 3 (9.09) | 258 | 14 (5.43) | 239 | 21 (8.79) | 0.0006 |
AI | 33 | 5 (15.15) | 258 | 117 (45.35) | 239 | 128 (53.56) | |
Tamoxifen | 33 | 14 (42.42) | 258 | 85 (32.95) | 239 | 58 (24.27) | |
LHRH + tamoxifen | 33 | 11 (33.33) | 258 | 42 (16.28) | 239 | 32 (13.39) | |
Year of diagnosis | |||||||
1980–1995 | 53 | 16 (30.19) | 298 | 12 (4.03) | 264 | 3 (1.14) | <0.0001 |
1996–2010 | 53 | 37 (69.81) | 298 | 286 (95.97) | 264 | 61 (98.86) | |